January 2023 | Targeted Therapies in Oncology

More Approaches Are Emerging in TP53-Mutated AML

January 23, 2023

Clinical Articles

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

Yu Highlights Possible Sequencing Strategies in mCRPC

January 22, 2023

Clinical Articles

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

Eftilagimod Alpha Combination Demonstrates Durable Responses in Frontline NSCLC

January 18, 2023

Clinical Articles

Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.

Early Promise Is Seen With CTX130 for RCC

January 18, 2023

Clinical Articles

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.

Despite Shortcomings, Key Learnings Gleaned From Phase 3 Trials

January 17, 2023

Clinical Articles

Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial design and achieve greater success in the future.